Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWadhwa, Aparna-
dc.contributor.authorVerma, Sandhya-
dc.contributor.authorKumar, Robin-
dc.contributor.authorSahu, Puran L-
dc.contributor.authorSingh, Abhishek-
dc.identifier.issn0975-0983(Online); 0376-4699(Print)-
dc.description.abstractDiclofenac is one of the top selling non steroidal anti-inflammatory drug (NSAID). It is available in wide range of dosage form for symptomatic relief of diverse inflammatory conditions. Presence of impurity in drug or drug products is a vital concern now a days for which stringent regulatory guidelines have been implemented to safeguard public health. Under these circumstances, presence of diclofenac impurity-A in diclofenac requires strict quality control to satisfy the specified regulatory limit. Therefore, the objective of the presence study is to synthesize diclofenac impurity-A in the purest form and its subsequent characterization by using a panel of sophisticated analytical techniques to provide as reference standard mentioned in most of the international compendiums including Indian Pharmacopoeia.en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-B Vol.58B(07) [July 2019]en_US
dc.subjectDiclofenac impurity-Aen_US
dc.subjectIndian pharmacopoeiaen_US
dc.subjectNon steroidal anti-inflammatory drugen_US
dc.subjectSymptomatic reliefen_US
dc.titleSynthesis and characterization of diclofenac impurity-A for the quality control of diclofenac and its formulation as per international compendiumsen_US
Appears in Collections:IJC-B Vol.58B(07) [July 2019]

Files in This Item:
File Description SizeFormat 
IJCB 58B(7) 855-860.pdf1.54 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.